Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Triple Negative Breast Neoplasms 4Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Pancreatic Neoplasms 3Head and Neck Neoplasms 3Biliary Tract Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Turcot syndrome 1Solid Tumor, Adult 1Rectal Neoplasms 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Hyperthermia 1Histiocytoma, Malignant Fibrous 1Glioma 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Efficacy 1Digestive System Neoplasms 1Dermatofibrosarcoma 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 3toripalimab 1spartalizumab 1sotorasib 1pazopanib 1palbociclib 1abemaciclib 1Trastuzumab 1Therapeutics 1Jupiter 1Interleukin-2 1Immune Checkpoint Inhibitors 1Fulvestrant 1EBI-005 1Cetuximab 1Catalytic Domain 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Tumor, Adult × Immune Checkpoint Inhibitors × Clear all
NCT04020185 2024-12-11

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

ImmuneSensor Therapeutics Inc.

Phase 1/2 Completed
40 enrolled 16 charts
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡